TTrialPathMatch Me to Trials
← Back to trials
RecruitingLong COVIDLong COVID SyndromeLong COVID-19 Syndrome

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are: * Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire. * Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation. Researchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms. Participants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.

Sponsor: University of New Mexico

You may qualify if…

  • 1. aged 18-80
  • 2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List
  • 3. have "brain fog" or cognitive difficulties as one of the ongoing symptoms
  • 4. are fluent in English
  • 5. if taking psychotropic medications, have been on stable doses for the past month.

You may not qualify if…

  • 1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;
  • 2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation
  • 3. history of ongoing substance/alcohol dependence, to reduce confounding effects on diagnosis and brain imaging
  • 4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS
  • 5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study
  • 6. any condition that would prevent the subject from completing the protocol
  • 7. appointment of a legal representative, to avoid coercion of a vulnerable population
  • 8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings

Where it's recruiting

New Mexico

Albuquerque

Source: ClinicalTrials.gov · NCT06940609 · last updated 2025-07-15